Filing Details

Accession Number:
0000899866-18-000041
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-08 19:17:33
Reporting Period:
2018-02-06
Accepted Time:
2018-02-08 19:17:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
899866 Alexion Pharmaceuticals Inc ALXN Pharmaceutical Preparations (2834) 133648318
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1655029 L Heidi Wagner C/O Alexion Pharmaceuticals, Inc
100 College Street
New Haven CT 06510
Svp, Global Government Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $.0001 Per Share Acquisiton 2018-02-06 14,577 $0.00 47,212 No 4 A Direct
Common Stock, Par Value $.0001 Per Share Acquisiton 2018-02-06 4,400 $0.00 51,612 No 4 A Direct
Common Stock, Par Value $.0001 Per Share Disposition 2018-02-08 1,774 $116.31 49,838 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
Footnotes
  1. On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 14,577 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary.
  2. On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 4,400 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary.
  3. This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.
  4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.